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Abstract 
The current study represents the first attempt to investigate the effect of the Euscaphic acid (EA) on Rats isolated  
thoracic aortic smooth muscle cells. Isolated aorta was used to test the anti-contraction effects and the possible 
mode of action(s) of the EA (1*10
-7
 M)
 
and (3*10
-7
 M) isolated from Crataegus azarolus var. aronia L. 
Euscaphic acid showed high anti-contraction effects on norepinephrin (NE), (1*10
-9
-10
-4
 M) induced contraction 
in aortic smooth muscle cells in endothelium-intact, endothelium-denuded, and aortic rings pre-incubated with 
potassium (K
+
)-channels blocker (tetraethylammonium, TEA), prostaglandin I2 (PGI2) inhibitor (indomethacin) 
and cyclic guanosine monophosphate (cGMP) inhibitor ( methylene blue). On the other hand, other K
+
 channels 
subtype blockers glibenclamide (GLIB); barium chloride (BaCl2) and 4-aminopyridine (4-AP) demonstrated that 
adenosine triphosphate sensitive K
+
 (KATP), inwardly rectifying K
+
 (Kir) and voltage-dependent K
+ 
(KV) channels 
played no role in anti-contraction induced by EA. Furthermore, the role of L-types calcium (Ca
++
) channels in 
EA anti-contractile effects on aortic smooth muscle cells was proved, by using the Ca
++
-channel blocker 
verapamil, as indicated by the production of a potent anti-contraction effect . The results of the current study 
indicate that the anti-contraction effects of EA may be due to the activation of calcium dependent, K
+ 
(KCa) 
channels and blocking of L-type Ca
++
 channels. Thus, from these results it can be concluded that both K
+
 and 
Ca
++
 channels play an important role in anti-contraction effects of EA, which are mediated possibly through 
opening of KCa channels and blockade of voltage-dependent calcium channels, which may justify the use of 
medicinal plant C. azarolus  in cardiovascular disease.  
Keywords: Crataegus azarolus var. aronia, Euscaphic acid, smooth muscle cells, K
+
-channels blockers, Ca
++
-
channels blocker. 
 
1- Introduction 
Medicinal herbs form an important part of folk medicine in most countries with a vital importance in treatment 
procedures (Rezaei et al., 2014). The use of alternative medicines is well documented in patients with chronic 
diseases such as hypertension, acute coronary syndrome, coronary heart disease, heart failure, peripheral arterial 
disease, and stroke (Charoonratana et al., 2014). 
Medicinal plants represent good sources for new, safe, biodegradable and renewable drugs and 
according to the World Health Organization (WHO) report (1993), about 65-80% of the developing countries 
populations depend essentially on plants and plant derived compounds for their primary healthcare needs (Roja 
et al., 2014). In modern pharmacy, about 50% of drugs are natural products derived from plants (Dhami, 2013). 
The newest drug discovery projects adoption based on  traditional medicinal plant strategy to assure their safety 
uses (Dhami, 2013; Mishra and Tiwari, 2011). In folk medicine, hawthorn leaves, flowers and fruits are 
important parts of the plant used as coronary vasodilator, cardiotonic, and hypotensive remedies (Keser et al., 
2014), and their phytochemical and pharmaceutical importance are reflected by the presence of bioactive 
compounds such as phenols, flavonoids, alkaloids, steroids, terpenoids and tannins in medicinal herbs and plants 
(Mirzaei and Mirzaei, 2013). 
The positive effects of Crataegus azarolus on the cardiovascular system have recently received a great 
scientific attention in phytotherapy (Caliskan et al., 2012). Bioactive compounds present in hawthorn include 
aromatic amines, essential oils, phenolic acids, flavonoids, proanthocyanidins (Keser et al., 2014) and triterpenes 
(Hu et al., 2014). In vitro and in vivo pharmacological investigations revealed that Euscaphic acid has a variety 
of biological activities, such as inhibitory effect against protein tyrosine phosphatase 1B (Li et al., 2014), 
enzymes involved in DNA replication (Jung et al., 2005), and lipid peroxidation (Marzouk, 2009).  Furthermore, 
it can inhibit atherosclerosis and xanthoma (Zhang et al., 2006), and decrease intracellular melanin content 
(Song et al., 2013). In addition, Euscaphic acid has diuretic, hepatoprotective (Lee et al., 2009), anti-
hyperglycemic, and antitumor-promoting (Kim et al., 2012), and antinociceptive properties (Jovel et al., 2007). 
However, since EA has been isolated for the first time from C. azarolus and no attempt has been made so far to 
study its effect on smooth muscle physiology, the present study aimed to investigate the anti-contraction effects 
of EA on a rat’s aortic smooth muscle cells with emphases on the role of endothelium-derived relaxing factors, 
Ca
++
 and K
+
 channels in its anti-contraction effects. 
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2- Materials And Methods 
Euscaphic acid from Crataegus aronia 
Euscaphic acid (Jacaranoic acid) was isolated for the first time from C. azarolus  ethyl acetate fraction, purified 
and identified after several analytical processes, including TLC (direct and reverse phase), column 
chromatography, 
1
H and 
13
C NMR spectra, ESI-MS spectrum …. etc. Detailed purification and identification 
procedures are fully described by Mahmud et al., (2015). 
 
Albino Rats 
Adult male albino rats, Rattus norvegicus weighing 200 – 300 gs,  used in the current study were bred in the 
Animal House, Department of Biology, Faculty of Science / University of Zakho and maintained in plastic cages 
(460 x 30 x 20 cm). They were kept under standard laboratory conditions at 22 ± 2 
o
C and exposed to a 
photoperiod of 12 hrs. light followed by 12 hrs. of darkness, using an automated light-switching devise. The rats 
were fed on standard rat pellets with free access to dechlorinated tap water ad libitum.  
 
Aorta Preparation and Experimental Protocols 
The rats were injected intraperitoneally (IP) with heparin, (1500 units/ kg body weight) and left for 30 min to 
avoid blood clotting and possible damage of endothelial layer of the aorta, and then anesthetized with ketamine 
(40 mg /kg) and Xylazine (10 mg/Kg) intraperitoneally. The chest cavity was opened, aorta was isolated and 
transferred into a petri-jar containing Krebs or calcium free Krebs solution, aerated with carbogen (95% O2 and 5% 
CO2) and maintained in a water bath at 37 
o
C. The aorta cut into rings of about 2-4 mm long and the first four 
rings of the aorta distal to aortic arch were taken to avoid the difference in the amplitude of contraction. 
The procedure described by Al-Habib and Shekha,( 2010) was followed with a slight modifications to 
study the vascular reactivity in isolated aorta. Two stainless steel wires were carefully passed through the lumen 
of the aortic rings, one of them was anchored to the base of glass organ bath chamber (Panlab/ Harvard, Model 
LE01046) and  the other wires was attached to a force transducer (ADInstruments, Australia, Model MLT0420),  
connected to a  transbridge amplifier (Quad Bridge Amplifier, Model FE 224, ADInstruments Pty Ltd., 
Australia), PowerLab Data Acquisition System (Model PL 3508, ADInstruments Pty Ltd., Australia) with 
computer running chart software (Version 7) (Model MLS060/7, ADInstrument, Australia)  used for  isometric 
tension measurement.    
 Prior to the experiment, the organ bath temperature was set at 37
 o
C for at least one hour, followed by 
the addition 10 ml of Kreb’s  with or calcium free solution to the tissue glass chamber. The preparation was 
aerated continuously with carbogen. Aortic rings were connected to the base of the chamber from one end and to 
the force transducer from the other end. The initial tension was set at 2 g weight and left for 60-90 min with 
changing the solution every 15 min. The aortic rings were initially exposed to 1µM (1*10
-6 
M) norepinephrin 
(NE) or 100µM (1*10
-4
 M) CaCl2 to test their functional integrity and 10µM (1*10
-5
 M) acetylcholine (ACh) to 
test endothelium integrity. This was followed by changing the bath solution several times until a stable resting 
tone was recorded  and then the  experiments were started. The anti-contraction effects of two doses of EA 
(1*10
-7
 M
 
and 3*10
-7
 M) on aortic rings post-contracted with different doses of NE (1*10
-9
-10
-4
 M) or CaCl2 
(1*10
-5
, 3*10
-5
, 1*10
-4
, 3*10
-4
, 1*10
-3
, 3*10
-3
 and 1*10
-2
 M) following an incubation period of 30 min. 
The present study included the following groups of experiments.  
Group I  
To study the anti-contraction effects of EA (1*10
-7
 M
 
and 3*10
-7
 M) on endothelium-intact (+E) aortic rings, 
post-contracted with different doses of NE (1*10
-9
-10
-4
 M), after pre-incubation of EA for 30 min. 
Group II 
To investigate the role of endothelial cells in anti-contraction effects of EA (1*10
-7
 M)
 
and (3*10
-7
 M) on 
endothelium-denuded (-E) aortic rings, post-contracted with different doses of NE (1*10
-9
-10
-4
 M), by gentle 
removal of endothelium. The removal of the endothelium was confirmed by the absence of relaxation induced by 
ACh (1*10
-5
 M) following NE (1*10
−6
 M) pre-contraction.  
Group III 
The role of endothelial nitric oxide (NO), cGMP and PGI2 in association with anti-contraction effects of EA 
(1*10
-7
 M
 
and 3*10
-7
 M) were evaluated, following pre-incubation of endothelium-intact aortic rings separately 
with each of NO synthase inhibitor, N-nitro-L-arginine methyl ester (L-NAME, 3*10
-4
 M), cGMP inhibitor, 
methylene blue (1*10
-5
 M) and PGI2 inhibitor, indomethacin (3*10
-5
 M) in combination with EA (1*10
-7
 M
 
and 
3*10
-7
 M) and then post-contracted with different doses of NE (1*10
-9
-10
-4
 M). 
Group IV 
To study the role of K
+
 channels in the development of the anti-contraction effects of EA (1*10
-7
 M
 
and 3*10
-7
 
M) on endothelium-intact aortic rings, the aortic rings were pre-incubated separately with each of the following 
K
+
 channels subtype blockers, KCa channels blocker,  (TEA, 1 mM),  KATP channels blocker, (GLIB, 1*10
-5 
M),  
Kir channels blocker, (BaCl2, 1mM) and KV channels blocker, (4-AP, 1 mM) in combination with EA (1*10
-7
 M
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and 3*10
-7
 M) post-contracted with different doses of NE (1*10
-9
-10
-4
 M).    
Group V 
To elucidate the role of Ca
++
 channels in anti-contraction effects induced by EA (1*10
-7
 M
 
and 3*10
-7
 M) in 
endothelium-intact aortic rings pre-incubated with L-type Ca
++
 channels blocker (verapamil 10nM (1*10
-8 
M), in 
combination with EA and then post-contracted with different doses of CaCl2 (1*10
-5
, 3*10
-5
, 1*10
-4
, 3*10
-4
, 
1*10
-3
, 3*10
-3
 and 1*10
-2
 M) was studied. 
Statistical Analysis  
All data were expressed as means ± SEM and the median effective concentrations (EC50) values are given as 
geometric mean with 95% confidence intervals (CI). The statistical analysis was performed using two-way 
analysis of variance (ANOVA) supported by Bonferroni test when carrying out a pairwise comparison between 
the same dose of different groups using Graphpad prism program (GraphPad Software, USA). P-values less than 
0.05 were considered as statistically significant. In all figures, the symbols *, ** and *** indicate that the 
differences between means are significant at 0.05, 0.01 and 0.001 levels, respectively. 
 
3- Results 
Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aorta 
Dose response-curves for EA anti-contraction effects on NE induced contraction in aortic rings are shown in 
Figure (1). Euscaphic acid at doses 1*10
-7
 M  and  3*10
-7 
M caused a highly significant (P<0.001) anti-
contraction effects on NE induced dose-dependent contraction at doses between  1*10
-7 
- 10
-4 
M in aortic rings as 
compared to the control rings. The Log EC50, (LogEC50 of CI 95%) and the % of contraction are shown in Table 
(1). Euscaphic acid at doses 1*10
-7
 M and 3*10
-7 
M produced a potent dose-dependent anti-contraction effect on 
NE induced contractions, with a LogEC50 -5.400 mg/mL (LogEC50 of CI 95% between -5.594 to -5.205) and -
4.791 mg/mL (LogEC50 of CI 95% between -5.477 to -4.105), respectively, where as in absence of EA, it was -
5.964 mg/mL (LogEC50 of CI 95% between -6.092 to -5.835). The amplitude of contraction in NE induced 
contraction in aortic rings was reduced from 100 ± 0.002 %, in aortic rings pre-incubated with EA at 
concentration 1*10
-7
 M and 3*10
-7 
M to 83.993 ± 0.003 % and 75.527 ± 0.003 %, respectively.  
 
Fig. 1. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in the 
rat’s endothelium-intact aortic rings. 
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Table 1. The LogEC50 (LogEC50 of CI 95%) and  contraction percent for the effects of pre-incubation with EA 
on NE post-contracted endothelium-intact aortic rings. 
Vasoconstrictor NE 
 
Treatments  
 
Control 
Euscaphic Acid  
1X10
-7
 M 
Euscaphic Acid  
3X10
-7 
M 
LogEC50 -5.964 -5.400 -4.791 
LogEC50 of CI 95% -6.092 to -5.835 -5.594 to -5.205 -5.477 to -4.105 
Contraction (%) ± SEM 100 ± 0.002  83.993 ± 0.003  75.527 ± 0.003  
 
Anti-contraction Effect of Euscaphic Acid on Endothelium-denuded Aorta 
Dose response-curves for the EA anti-contraction effects on NE induced contraction in endothelium-denuded 
aortic rings are shown in Figure (2). Both EA doses (1*10
-7
 M and 3*10
-7 
M) caused a highly significant 
(P<0.001) anti-contraction effects on  NE induced dose-dependent contraction  (between 1*10
-7 
- 10
-4 
M) in the 
aortic rings as compared to the control aortic rings. Euscaphic acid at a concentration of 1*10
-7
 M produced a 
potent effect on NE induced contractions, with a LogEC50 -5.493 mg/mL (LogEC50 of CI 95% between -5.676 to 
-5.311), whereas EA at a concentration 3*10
-7 
M produced a further, but limited anti-contraction effect with 
LogEC50 -5.336 mg/mL (LogEC50 of CI 95% between -5.496 to -5.175), as compared with that of the control 
(absence of EA) in which the LogEC50 was -6.240 mg/mL (LogEC50 of CI 95% between -6.424 to -6.056) 
(Figure 2 and  Table 2 ). Also EA at a concentration of 1*10
-7
 M showed much of its anti-contraction effect on 
aortic rings since the amplitude of contraction was reduced from 100.00 to 84.999 %, whereas at a higher EA 
dose (3*10
-7
 M), it was further reduced, but   to a lesser extent, to 80.086% (Table 2). 
 
Fig. 2. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat 
endothelium-denuded aortic rings. 
 
Table 2. The LogEC50 (LogEC50 of CI 95%) and % of contraction for the effects of pre-incubation with EA on 
NE post-contracted endothelium-denuded aortic rings. 
Vasoconstrictor NE 
Treatments  Control Euscaphic Acid 1X10
-7
 
M 
Euscaphic Acid 3X10
-7 
M 
LogEC50 -6.240 -5.493 -5.336 
LogEC50 of CI 95% -6.424 to -6.056 -5.676 to -5.311 -5.496 to -5.175 
Contraction (%) ± SEM 100 ± 0.004  84.999 ± 0.006  80.086 ± 0.001  
 
Anti-contraction Effect of EA on Aortic Rings Pre-incubated individually with L-NAME (NO Synthase 
Inhibitor), Indomethacin (PGI2 Inhibitor ) and Methylene blue ( cGMP Inhibitor):   
Anti-contraction Effect of EA on Aortic Rings Pre-incubated with L-NAME (NO Synthase Inhibitor): 
Dose response-curves for EA anti-contraction effects on NE induced contraction in aortic rings pre-incubated 
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with L-NAME (3*10
-4 
M) are shown in Figure (3).  Euscaphic Acid at both doses 1*10
-7
 M and 3*10
-7 
M0 didn’t 
showed any significant effect on aortic rings pre-incubated with L-NAME, (the inhibitor of NO) and post-
contracted with different doses of NE. 
 
Fig. 3. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat 
aortic rings pre-incubated with L-NAME (3*10
-4 
M). 
 
Anti-contraction Effect of EA on Endothelium-intact Aortic Rings Pre-incubated with Indomethacin 
(PGI2 Inhibitor) 
Dose response-curves for the anti-contraction effects of EA on NE induced contraction in aortic rings pre-
incubated with indomethacin (3*10
-5 
M) are shown in Figure (4). Euscaphic acid doses 1*10
-7
 M and 3*10
-7 
M 
produced a highly significant (P<0.001) anti-contraction effects on NE induced dose-dependent contraction ( at 
doses between 1*10
-6 
–10
-4 
M)  in aortic rings pre-incubated with indomethacin. The LogEC50, (LogEC50 of CI 
95%) and the % of contraction are shown in Table (3). Euscaphic acid at a concentration 1*10
-7
 M  had more 
potent anti-contraction effect on NE induced contraction in aortic rings pre-incubated with indomethacin with 
LogEC50 -5.440 mg/ml (LogEC50 of CI 95% between -5.668 to -5.211). Furthermore, EA at a concentration of 
3*10
-7 
M, also showed a further anti-contraction effect, but to a lesser extent, on NE post-contracted aortic rings 
pre-incubated with indomethacin, with LogEC50 -5.250 mg/ml (LogEC50 of CI 95% between -5.705 to -4.796), 
while the LogEC50 was -5.692 mg/ml (LogEC50 of CI 95% between -5.871 to -5.513) in NE post-contracted 
aortic rings pre-incubated with indomethacin  in the absence of EA. Euscaphic acid at a low concentration (1*10
-
7 
M)  produced most of its anti-contraction effect in which the  amplitude  of contraction was reduced from 
100.00 to 81.122%, whereas  at a higher concentration of EA (1*10
-7 
M), the amplitude of contraction  was 
further reduced, but at a slower rate,  to 76.468%.      
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Fig. 4. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat 
aortic rings pre-incubated with indomethacin (3*10
-5 
M). 
 
Table 3. The LogEC50 (LogEC50 of CI 95%) and % of contraction for the effects of pre-incubation EA on NE 
post-contracted aortic rings pre-incubated with indomethacin (3*10
-5 
M). 
Vasoconstrictor NE 
 
Treatments 
Control 
Indomethacin 3X10
-5 
M 
Euscaphic Acid 1X10
-7
 M  
+ 
Indomethacin 3X10
-5 
M 
Euscaphic Acid 3X10
-7
 M  
+ 
Indomethacin 3X10
-5 
M 
LogEC50 -5.692 -5.440 -5.250 
LogEC50 of CI 95% -5.871 to -5.513 -5.668 to -5.211 -5.705 to -4.796 
Contraction (%) ± SEM 100 ± 0.0005  81.122 ± 0.0006  76.468 ± 0.001  
 
Anti-contraction effect of Euscaphic Acid on endothelium-intact aortic rings pre-incubated with 
methylene blue (cGMP Inhibitor) 
Dose response-curves for EA anti-contraction effects on NE induced contraction in aortic rings pre-incubated 
with methylene blue (1*10
-5 
M) are shown in Figure (5). Euscaphic acid doses between 1*10
-7
 M and 3*10
-7 
M 
caused highly significant (P<0.01 - < 0.001) anti-contraction effects on NE induced contraction in rats aortic 
rings at NE concentrations  between 1*10
-7 
M and 1*10
-8  
to 10
-4 
M. The LogEC50, (LogEC50 of CI 95%) and the % 
of contraction are shown in Table (4). Euscaphic acid at a concentration of 1*10
-7
 M produced a moderate anti-
contraction effect on NE induced contractions, with a LogEC50 -7.331 mg/ml (LogEC50 of CI 95% between -
7.583 to -7.078), whereas EA at a higher concentration (3*10
-7 
M),  produced a more potent anti-contraction 
effect with LogEC50 -7.147 mg/ml (LogEC50 of CI 95% between -7.396 to -6.898), as compared with the control 
experiment, in which the LogEC50 was -7.847 mg/ml (LogEC50 of CI 95% between -8.146 to -7.548) in absent of 
EA. Furthermore, also EA at concentrations 1*10
-7
 M and 3*10
-7
 M , produced potent anti-contraction effects on 
aortic rings since the amplitude of contraction was reduced from 100.00 (in the absence of EA) to 76.984 and 
57.089%, respectively.  
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Fig. 5. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat 
aortic rings pre-incubated with methylene blue (1*10
-5 
M). 
 
Table 4. The LogEC50 (LogEC50 of CI 95%) and contraction (%) ± SEM for the effects of pre-incubation EA on 
NE post-contracted aortic rings pre-incubated with methylene blue (1*10
-5 
M). 
Vasoconstrictor NE 
 
 
Treatments  
 
Control 
Methylene blue 1X10
-5 
M 
Euscaphic Acid 1X10
-7
 
M 
+ 
Methylene blue 1X10
-5 
M 
Euscaphic Acid 3X10
-7
 
M 
+ 
Methylene blue 1X10
-5 
M 
LogEC50 -7.847 -7.331 -7.147 
LogEC50 of CI 95% -8.146 to -7.548 -7.583 to -7.078 -7.396 to -6.898 
Contraction (%) ± 
SEM 
100 ± 0.01  76.984 ± 0.008  57.089 ± 0.008  
Anti-contraction Effect of Euscaphic Acid on K
+
 Channels  Subtype in Endothelium-intact Aorta Rings: 
Anti-contraction Effect of Euscaphic Acid  on KCa Channel in Endothelium-intact Aortic Rings 
Dose response-curves for the EA anti-contraction effects on NE induced contraction in aortic rings pre-incubated 
with KCa channel blocker, TEA (1*10
-3 
M) are shown in Figure (6). Both EA doses, 1*10
-7
 M and 3*10
-7 
M, 
caused a significant (P<0.01) anti-contraction effect on NE induced dose-dependent contractions at doses   
between 1*10
-6
-10
-4 
M and 1*10
-7
-10
-4 
M, respectively.  In aortic rings pre-incubated with TEA, EA at a 
concentration of 1*10
-7
 M produced a weak anti-contraction effect in NE induced contractions, with a LogEC50 -
5.578 mg/ml (LogEC50 of CI 95% between -5.723 to -5.434), whereas at a higher EA concentration (3*10
-7 
M),  
a more potent anti-contraction effect was produced with LogEC50 -5.420 mg/ml (LogEC50 of CI 95% between -
5.554 to -5.286), as compared with that of the control in which the LogEC50 was -5.725 mg/ml (LogEC50 of CI 
95% between -5.901 to -5.549). Furthermore, EA at a concentration (1*10
-7
 M) showed a moderate anti-
contraction effect on NE induced contraction in aortic rings pre-incubated with TEA since the amplitude of 
contraction was reduced from 100 ± 0.002 % to 91.479 ± 0.002 %, whereas at a higher EA dose (3*10
-7
 M), the 
anti-contraction effect on NE induced contraction in aortic rings pre-incubated with TEA was further enhanced, 
and reduced to 87.01 as compared with the control.  
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Fig. 6. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat 
aortic rings pre-incubated with TEA (1*10
-3 
M).  
 
Table 5. The LogEC50 (LogEC50 of CI 95%) and contraction (%) ± SEM for the effects of pre-incubation with 
EA on NE post-contracted aortic rings pre-incubated with TEA (1*10
-3 
M). 
Vasoconstrictor NE 
 
Treatments  
Control 
 
TEA 1X10
-3 
M 
Euscaphic Acid 1X10
-7
 
M 
+ 
TEA 1X10
-3 
M 
Euscaphic Acid 3X10
-7
 M 
+ 
TEA 1X10
-3 
M 
Log EC50 -5.725 -5.578 -5.420 
Log EC50 of CI 95% -5.901 to -5.549 -5.723 to -5.434 -5.554 to -5.286 
Contraction (%) ± SEM 100.00 ± 0.002  91.479 ± 0.002  87.008 ± 0.001  
 
Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aortic Rings Pre-incubated with GLIB 
(KATP Channel Blocker) 
Dose response-curves for the anti-contraction effects of EA on NE induced contraction in aortic rings pre-
incubated with GLIB (1X10
-5 
M) are shown in Figures (7).  Both EA doses, 1*10
-7
 M and 3*10
-7 
M used didn’t 
showed any significant effects on aortic rings pre-incubated with GLIB and post-contracted with different doses 
of NE. 
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Fig. 7. Cumulative dose-response curves for the effects of EA on NE induced contraction in rat aortic rings pre-
incubated with GLIB (1*10
-5 
M). 
 
Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aorta Rings Pre-incubated with BaCl2 
(Kir Channel Blocker) 
Dose response-curves for anti-contraction effects of EA  on NE induced contraction in aortic rings pre-incubated 
with BaCl2 (1X10
-3 
M) are shown in Figure (8).  Both EA doses 1*10
-7
 M and 3*10
-7 
M also didn’t showed any 
significant anti-contraction effect on aortic rings pre-incubated with BaCl2 and induced contraction with different 
doses of NE. 
 
Fig. 8. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat 
aortic rings pre-incubated with BaCl2 (1*10
-3 
M). 
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Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aorta Rings Pre-incubated with 4-AP 
(KV Channel Blocker) 
Dose response-curves for anti-contraction effects of EA on NE induced contraction in aortic rings pre-incubated 
with 4-AP (1*10
-3 
M) are shown in Figure (9).  Euscaphic acid doses 1*10
-7
 M and 3*10
-7 
M didn’t produced any 
significant anti-contraction effect on aortic rings pre-incubated with 4-AP and induced contraction with different 
doses of NE. 
 
Fig. 9. Cumulative dose-response curves for the anti-contraction effects of EA on NE induced contraction in rat 
aortic rings pre-incubated with 4-AP (1*10
-3 
M).  
 
Anti-contraction Effect of Euscaphic Acid on Endothelium-intact Aorta Rings Pre-incubated with 
Verapamil (L-type Ca
++
 Channel Blocker)  
Dose response-curves for anti-contraction effects of EA on CaCl2 induced contraction in aortic rings pre-
incubated with verapamil (1*10
-8 
M) are shown in Figure (10). Euscaphic acid doses 1*10
-7
 M and 3*10
-7 
M 
produced a highly significant (P<0.001) anti-contraction effect on CaCl2 induced contraction at concentrations 
between 1*10
-4
  and 1*10
-2
 M  in aortic rings pre-incubated with verapamil. The LogEC50, (LogEC50 of CI 95%) 
and the amplitude of contraction are shown in Table (6). Euscaphic acid at doses 1*10
-7
 M and 3*10
-7 
M 
produced  significant (P<0.05 to 0.001) effects on CaCl2 induced contraction in aortic rings pre-incubated with 
verapamil with LogEC50 -3.740 mg/ml (LogEC50 of CI 95% between -3.946 to -3.533) and -3.795 mg/ml (Log 
EC50 of CI 95% between -3.961 to -3.628), respectively, as compared with the control experiments (in absent of 
EA), in which the LogEC50 was -3.992 mg/ml (LogEC50 of CI 95% between -4.088 to -3.897). Furthermore, EA 
at doses 1*10
-7
 M and 3*10
-7 
M produced strong anti-contraction effects on aortic rings pre-incubated with 
verapamil in which the amplitude  of contraction was reduced from 100 ± 0.002 % (in the absence of EA) to 
86.572 ± 0.001 % and 62.351 ± 0.0007 %, respectively.   
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Fig. 10. Cumulative dose-response curves for the anti-contraction effects of EA on CaCl2 induced contraction in 
rat aortic rings pre-incubated with verapamil (1*10
-8 
M). 
 
Table 6. The LogEC50 (LogEC50 of CI 95%) and contraction (%) ± SEM for the effects of pre-incubation with 
EA on CaCl2 post-contracted aortic rings pre- incubated with verapamil (1*10
-8 
M). 
Vasoconstrictor NE 
 
Treatments  
 
Control 
Verapamil 1X10
-8 
M 
Euscaphic Acid 1X10
-7
 
M 
+ 
Verapamil 1X10
-8 
M 
Euscaphic Acid 3X10
-7
 
M 
+ 
Verapamil 1X10
-8 
M 
LogEC50 -3.992 -3.740 -3.795 
LogEC50 of CI 95% -4.088 to -3.897 -3.946 to -3.533 -3.961 to -3.628 
Contraction (%) ± SEM 100 ± 0.002  86.572 ± 0.001  62.351 ± 0.0007  
 
4- Discussion 
The current study was performed to investigate the possible  anti-contraction effects of the novel triterpenoid EA 
isolated from Crataegus azarolus var. aronia on rat aortic smooth muscle at doses 1*10
-7
 M and 3*10
-7 
M.  
Euscaphic acid produced anti-contraction effects on aortic smooth muscle cells in association with endothelium-
derived relaxing factors, K
+
 and L-type Ca
++
 channels. The results of the current study represents the first report 
on the anti-contraction effect of EA on rat aortic rings smooth muscle, after its isolation for the first time from C. 
azarolus . 
The results clearly indicated that the inhibitory effect of EA on the contraction of aortic smooth muscle 
in association with production of PGI2, since the use of indomethacin (a nonspecific cyclooxygenase inhibitor) 
showed that PGI2 plays an important role in EA vasodilator effect. Since no data are available on the effect of 
Euscaphic acid-induced relaxant effect on aortic smooth muscle, it is difficult to compare the results. However, 
Aguirre-Crespo et al., (2005) showed that the vasodilator effect of other triterpenoids isolated from L. caulescens 
was produced via cyclooxygenase synthase pathway. Wongsawatkul et al., (2008), demonstrated that the 
relaxant effect of Spilanthes acmella extract containing phenolic and triterpenoids is produced partially via 
endothelium induced PGI2 production. Recently, Dood et al., (2013), suggested that the hawthorn induced the 
production of prostacyclin in rat smooth muscle cells (SMCs) and since EA is one of the active constituent of 
hawthorn, it may acts via the production of prostacyclin. 
The mechanism by which PGI2 inhibits smooth muscle contraction includes the activation of adenylyl 
cyclase via the specific cell surface IP receptor-coupled guanine nucleotide regulatory protein, Gs, which in turn 
elevates intracellular adenosine 3’:5’-cyclic monophosphate (cAMP) levels (Yamaki et al., 2001). Increased 
intracellular concentration of cAMP inhibits the sensitivity of the contractile proteins to Ca
++
 ions (Clyman, 
2006). 
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The results of the current study showed that cGMP has an important role on the anti-contraction effect 
of EA on aortic smooth muscle since the use of methylene blue (cGMP inhibitor) demonstrated clearly the role 
of cGMP in EA anti-contractile effects. According to our data, EA induce the production cGMP in endothelial 
cells, which in turn decreases the contraction of smooth muscle cells. This conclusion is supported by the 
observation that the guanylate cyclase inhibitor methylene blue reduced the relaxant effect of EA. Nitric oxide 
once released from the endothelium, diffuses into the arterial smooth muscle fibers to activate guanylate cyclase 
and thus increases cytoplasmic cGMP levels, leading to vasorelaxation in rat isolated mesenteric arteries (Chen 
et al., 1998). It has been reported that  triterpenoids have significant endothelium-dependent vasorelaxant effect 
in rat aortic SMC through NO release (Rios et al., 2012), and  since EA is triterpenoids, it may possibly act via 
inducing NO, which activate guanylate cyclase and in turn increases cGMP level and leading to vasorelaxation. 
The mechanism of cGMP action in vasodilation activity was explained by Gadelha de Cerqueira et al., 
(2012), which includes that cGMP activates intracellular effectors, such as protein kinase G (PKG), which 
causes diminishing of intracellular Ca
++
 ions and disassociation of actin and myosin filaments and ultimately 
leading to relaxation of the smooth muscle cells. Furthermore, they also explained the interaction of cGMP-
cAMP cell signaling systems in the relaxation of smooth muscle. In other words, cGMP activates PKG, and then 
mediates vascular relaxation through phosphorylation of various targets (Hildebrand et al., 2013). 
The results compiled from the effect of TEA (KCa channels blocker) on anti-contraction effect of EA 
on aortic smooth muscle cells indicate that KCa channels play a prominent role in increasing its anti-contractile 
effect and revealed that EA activate the KCa channels, but not other K
+
 channels subtypes  such as KATP, Kir and 
KV channels. These observations are in partial agreement with those reported by Chen et al., (1998), since they 
found that KCa channels, using a potent KCa channels inhibitor Iberiotoxin, plays a minor role in relaxant action 
hawthorn extract. Furthermore, they added that GLIB fail to change the vasorelaxation action of Crataegus 
extract in rat arterial SMCs. 
The role of L-type Ca
++
 channel in smooth muscle contraction has been demonstrated by Fransen et al., 
(2012), and they showed that it is responsible for regulating the influx of Ca
++
 into muscle cells, which in turn 
stimulates smooth muscle contraction. Euscaphic acid used in the present study produced a sharp anti-
contraction effect on aortic rings pre-incubated with verapamil (L-type Ca
++
 channel blocker). This proves that 
EA blocks the activity of L-type Ca
++
 channels which in turn leads to aortic vasorelaxation. Al-Surchi, (2010) 
working on the inhibitory effect of C. azarolus extract on rat’s aortic smooth muscle claimed that this effect may 
be due to the interference of  active ingredient present in the extract such as triterpenoids either with Ca
++
 release 
from SR or with Ca
++
 influx through voltage gated L-type Ca
++
 channels located in the plasma membrane of 
smooth muscle cells.  Furthermore, Chen et al., (1998) reported that hawthorn extract may have a direct 
inhibitory effect on Ca
++
 entry through voltage-sensitive Ca
++
 channels in smooth muscle cell membrane. 
 
5- Conclusions 
From the results of the current study it has been concluded that EA has anti-contractile and cardioprotective 
effects which are mediated possibly through enhancement of   the production of endothelium-derived relaxing 
factors (particularly cGMP and PGI2). Furthermore, EA also block Ca
++
 channels and ultimately Ca
++
 release 
from intracellular stores house and increase the K
+
 conduction via increasing Kca channels activity. These 
observations might be justifying the medicinal use of EA which isolated from C. azarolus in hypertension and 
other cardiovascular diseases. However, more studies are required to establish the safety, efficacy and activity of 
this compound. 
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